Related Experiment Video
Updated: Mar 3, 2026
04:03
Application of Laparoscopic Ultrasonography in Primary Choledochal Suture during Combined Two-lens Surgery
Published on: March 28, 2025
579
What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Lin Lee Wong1, Vinod S Hegade, David E J Jones
1NIHR Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.
Digestive Diseases (Basel, Switzerland)
|May 4, 2017
Summary
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease. While ursodeoxycholic acid (UDCA) is a primary therapy, obeticholic acid (OCA) offers an alternative for non-responders, though clinical outcomes require further study.
Area of Science:
- Hepatology
- Autoimmune Diseases
- Pharmacology
Background:
- Primary biliary cholangitis (PBC) is a rare autoimmune liver disease causing chronic cholestasis.
- Ursodeoxycholic acid (UDCA) is the standard therapy, delaying progression by mitigating cholestatic injury.
- Inadequate response to UDCA predicts disease progression, liver transplantation, and mortality.
Purpose of the Study:
- To review the efficacy and safety of obeticholic acid (OCA) as a second-line therapy for PBC.
- To discuss the current landscape of PBC treatment, including UDCA, OCA, and emerging therapies.
- To highlight unmet needs in PBC management, particularly regarding clinical outcomes and symptom control.
Main Methods:
- Review of clinical trial data and regulatory approvals for OCA in PBC.
- Analysis of biochemical and clinical outcome data for UDCA and OCA.
- Discussion of ongoing research into novel PBC therapeutics and symptom management strategies.
Main Results:
- Obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, is approved for UDCA non-responders.
- OCA demonstrates compelling biochemical improvements but lacks evidence for improving hard clinical outcomes or quality of life.
- OCA may exacerbate pruritus in some PBC patients; novel agents are under investigation for improved side-effect profiles.
Conclusions:
- OCA provides a biochemical treatment option for PBC patients with inadequate UDCA response.
- Further research is needed to establish OCA's impact on long-term clinical outcomes and quality of life.
- Development of novel agents with better safety profiles and efficacy for symptom management is crucial for advancing PBC care.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
440
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
440
01:17Chronic Bowel Disorders: Introduction
855
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
855
01:26Peptic Ulcer Disease IV: Management
578
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
578
01:30Acute Pancreatitis II: Clinical Manifestations and Management
964
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
964
01:29Inflammatory Bowel Disease IV: Pharmacological Management
868
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
868
01:29Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577